Telephonic blind assessment on the adhesion to the therapy with a long-acting beta2-adrenergic and a steroid separately administered or associated in a single device in mild-to-moderate asthmatics;Associazione estemporanea o precostituita di beta2-adrenergico long-acting e steroide inalatorio nell'asma persistente lieve-moderato: Indagine telefonica in cieco per la valutazione della adesione alla terapia

GIMT - Giornale Italiano delle Malattie del Torace

Volumn 56, Issue 6, 2002, Pages 442-447

  Dal Negro, R W ^a   Micheletto, C ^a   Bisato, R ^a   Trevisan, F ^a   Pomari, C ^a   Tognella, S ^a  

^a Ospedale Orlandi   (Italy)

Author keywords

Bronchial asthma; Compliance; Inhaled combination 2 agonists+corticosteroids

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; FLUTICASONE PROPIONATE PLUS SALMETEROL; STEROID;

ADULT; ARTICLE; ASTHMA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEVICE; DISEASE SEVERITY; FEMALE; HUMAN; MALE; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; TELEPHONE; TREATMENT OUTCOME;

EID: 41149174317     PISSN: 11270810     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Expert Panel Report II: Guideliness for the Diagnosis and Management of Asthma. National Asthma Education and Prevention Asthma. National Institute of Health Publication 97-4501. Bethesda, Maryland, US 1997.
2. Bosley CM, Parry DT, Cochrane GM. Patient compliance with inhaled medication: does combining beta-agonists with corticosteroids improve compliance? Eur Respir J 1994: 7: 504-9.
3. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23: 1296-310.
4. Dompeling E, Vansgrunsven PM, Van Schayckn CP, Folgering H, Molena J, Van Weel C. Treatment with inhaled corticosteroids in asthma and chronic bronchitis: long-term compliance with inhaler technique. Fam Pract 1992; 92: 161-6.
5. Sacket DL, Snow JC. The magnitude of compliance and non-compliance. In Haynes RB, Taylor DW, Sackett DL eds. Compliance in Health Care. Baltimore, John Hopkins University Press 1979; 11-22.
6. Price DB. Perceived asthma compliance related to symptom control and patient attitudes. Thorax 1995; 50 (Suppl 2): A53.
7. Horn CR, Clark TJH, Cochrane GM. Compliance with inhaled therapy and morbidity for asthma. Resp Med 1990; 84: 67-70.
8. British Thoracic Association. Death from asthma in two regions of England. Br Med J 1982; 285: 1251-5.
9. Kavuru M, Melamed J, Gross G, LaForce C, House K, Prillaman B, Baitinger L, Woodring A, Shah T. Salmeterol and Fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 2000; 105:1108-16.
10. Aubier M, Pieters WR, Schlosser NJ, Steinmetz K-O. Salmeterol/Fluticasone propionate (50/500 μg) in combination in a Diskus® inhaler is effective and safe in the treatment of steroid-dependent asthma. Respir Med 1999; 93: 876-84.
11. Kips JC, O'Connor BJ, Inman MD, Svensson K, Pauwels RA, O'Byrne PM. A long-term study of the inflammatory effects of low-dose budesonide plus formoterol versus high-dose budesonide in asthma. Am J Respir Crit Care Med 2000; 161: 996-1001.
12. 2-agonists and corticosteroids. Eur Resp J 2002; 19: 182-91.
13. Mc Carthy TP, Russel MS, Rice L, Patel S. Improved patient compliance with salmeterol/fluticasone propionate combination compared with regular long-acting β2 agonist and inhaled steroid therapy. Eur Resp J 2002; 20 (suppl. 38): P3874.
14. Campbell LM. Once-daily inhaled corticosteroids in mild to moderate asthma: improving acceptance of treatment. Drugs 1999; 58 (suppl 4): 25-33
15. Cochrane GM. Compliance in asthma: a European perspective. Eur Resp J 1995; 5: 116-9.
16. Jones PW. Health status, quality of life and compliance. Eur Respir Rev 1998; 8: 56, 243-6.
17. C Micheletto, S Tognella, C Pomari, R Dal Negro. Fluticasone P. 250 meg bid e reattività bronchiale alla mch nell'asma lieve persistente. Studio a 5 anni sul ruolo dell'aderenza long-term alla terapia. 3° Congresso Nazionale di Pneumologia, Roma 6-9 novembre 2002.
18. Djukanovic R. Airway inflammation in asthma and its consequences: implications for treatment in children and adults. J Allergy Clin Immunol 2002; 109: S539-48.
19. Bosley CM, Fosbury JA, Cochrane GM. The psychological factors associated with poor compliance in the treatment in asthma. Eur Resp J 1995; 8: 899-904.
20. Bender BG. Overcoming barriers to no-nadherence in asthma treatment. J Allergy Clin Immunol 2002; 109: S554-9.
21. Horne R, Weinman J. Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Resp 1999; 47: 555-67.
22. Nelson HS. Advair: combination treatment with fluticasone propionate/salmeterol in the treatment of asthma. J Allergy Clin Immunol 2001; 107: 397-416.
23. O'Byrne PM, Barnes PJ, Rodriguez-Roisin R. Low dose inhaled budesonide and formoterol in mild persistent asthma. Am J Respir Crit Care Med 2001; 164: 1392-7.